Follow Protagonist Therapeutics to never miss an important update.
BMO Capital raised its price target for the company to $178 from $112 while keeping its outperform rating, which is a signal that they expect the stock to do better than the broader market. This update follows a period where several other major firms have also increased their price targets.
The higher target reflects growing confidence in the company's transition from a research-focused firm to a profitable one. With one major drug already approved and another nearing a decision from the FDA, the firm's model of collecting royalties from larger partners is gaining more traction with analysts.
Source: BMO Capital
Wedbush significantly raised its price target for the company, moving it from $118 to $173. A jump of this size usually happens when an analyst sees a major shift in the company's ability to generate cash or a lower risk for its upcoming drug approvals.
The firm is likely looking toward the expected late-2026 approval of the company's second major drug. If that drug for blood disorders reaches the market, it would trigger large payments from partners and further cement the company's transition into a profitable business.
Source: Wedbush
Goldman Sachs set a new price target of $186 for the company. This is a notable call from one of the most widely followed firms on Wall Street, and the target sits significantly higher than where the stock trades today.
Setting a high target like this suggests the firm believes the market is still underestimating the value of the company's oral peptide technology. By turning injectable drugs into pills, the company makes treatments easier for patients to take, which can lead to much higher sales and royalty checks over time.
Source: Goldman Sachs
Truist Financial raised its price target for the company to $170. This move reflects growing confidence in the business following its recent earnings report and the progress of its drug pipeline.
For a company like this, which relies on large partners to sell its drugs, analyst targets often move based on how quickly those partners can gain market share. The new target suggests the firm sees more room for the stock to grow as royalty payments begin to scale up.
Source: Truist Financial
Barclays analysts raised their price target for the stock from $151 to $153 while keeping an overweight rating. This is a small adjustment after the company reported its first full quarter of sales for its new psoriasis drug. It suggests the firm remains confident that the drug launch is on the right track.
Source: Barclays
The company has beaten analyst profit targets for two straight quarters. This suggests management is clearing the bar easily as royalty checks from partners start to outweigh research costs.
| Expectation | |
|---|---|
| EPS | $2.19 |
| Revenue | $220M |
Follow Protagonist Therapeutics to get the latest and most important updates.
Follow PTGX